Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors

Mahboobe Ghaedi, Masoud Soleimani, Narges Mohammad Taghvaie, Mahmood Sheikhfatollahi, Keyhan Azadmanesh, Abbas S. Lotfi, Jian Wu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Inhibition of tumor-induced angiogenesis may restrict tumor growth and metastasis. Long-term systemic delivery of angiogenic inhibitors is associated with toxicity, as well as other severe side-effects. The utility of cells as vehicles for gene therapy to deliver therapeutic molecules has been suggested to represent an efficient approach. Mesenchymal stem cells (MSCs) exhibit a tropism to cancer tissue, and may serve as a cellular delivery vehicle and a local producer of anti-angiogenic agents. Methods: In the present study, we attempted to assess production of the transgene, α1-antitrypsin (AAT), in lentivirus-transduced human MSCs and its cytotoxicity against human umbilical cord vein endothelial cells (HUVEC). The secreted protein from these effector cells was determined by an enzyme-linked immunosorbent assay. The cytotoxicity of hMSCs that overexpress the human AAT gene against HUVEC was evaluated with an apoptotic assay. Results: Lentivirus-transduced hMSCs produced functional AAT and displayed much higher cytotoxicity against HUVEC than untransduced hMSCs. Moreover, AAT secreted from transduced hMSCs significantly inhibited HUVEC proliferation compared to untransduced hMSCs. The data obtained demonstrate for the first time that genetically modified hMSCs released abundant and functional AAT that caused obvious cytotoxicity to HUVEC. Conclusions: hMSC may serve as an effective platform for the targeted delivery of therapeutic proteins to cancer sites.

Original languageEnglish (US)
Pages (from-to)171-180
Number of pages10
JournalJournal of Gene Medicine
Volume13
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Angiogenic Proteins
Umbilical Cord
Human Umbilical Vein Endothelial Cells
Mesenchymal Stromal Cells
Lentivirus
Neoplasms
Tropism
Angiogenesis Inhibitors
Transgenes
Genetic Therapy
Proteins
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Neoplasm Metastasis
Therapeutics
Growth
Genes

Keywords

  • α1-antitrypsin
  • Angiogenesis
  • Cancer gene therapy
  • Mesenchymal stem cells
  • Umbilical cord vein endothelial cells

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

Ghaedi, M., Soleimani, M., Taghvaie, N. M., Sheikhfatollahi, M., Azadmanesh, K., Lotfi, A. S., & Wu, J. (2011). Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. Journal of Gene Medicine, 13(3), 171-180. https://doi.org/10.1002/jgm.1552

Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. / Ghaedi, Mahboobe; Soleimani, Masoud; Taghvaie, Narges Mohammad; Sheikhfatollahi, Mahmood; Azadmanesh, Keyhan; Lotfi, Abbas S.; Wu, Jian.

In: Journal of Gene Medicine, Vol. 13, No. 3, 03.2011, p. 171-180.

Research output: Contribution to journalArticle

Ghaedi, M, Soleimani, M, Taghvaie, NM, Sheikhfatollahi, M, Azadmanesh, K, Lotfi, AS & Wu, J 2011, 'Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors', Journal of Gene Medicine, vol. 13, no. 3, pp. 171-180. https://doi.org/10.1002/jgm.1552
Ghaedi M, Soleimani M, Taghvaie NM, Sheikhfatollahi M, Azadmanesh K, Lotfi AS et al. Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. Journal of Gene Medicine. 2011 Mar;13(3):171-180. https://doi.org/10.1002/jgm.1552
Ghaedi, Mahboobe ; Soleimani, Masoud ; Taghvaie, Narges Mohammad ; Sheikhfatollahi, Mahmood ; Azadmanesh, Keyhan ; Lotfi, Abbas S. ; Wu, Jian. / Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. In: Journal of Gene Medicine. 2011 ; Vol. 13, No. 3. pp. 171-180.
@article{c5c9197b08f14f72af3bd479481c3474,
title = "Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors",
abstract = "Inhibition of tumor-induced angiogenesis may restrict tumor growth and metastasis. Long-term systemic delivery of angiogenic inhibitors is associated with toxicity, as well as other severe side-effects. The utility of cells as vehicles for gene therapy to deliver therapeutic molecules has been suggested to represent an efficient approach. Mesenchymal stem cells (MSCs) exhibit a tropism to cancer tissue, and may serve as a cellular delivery vehicle and a local producer of anti-angiogenic agents. Methods: In the present study, we attempted to assess production of the transgene, α1-antitrypsin (AAT), in lentivirus-transduced human MSCs and its cytotoxicity against human umbilical cord vein endothelial cells (HUVEC). The secreted protein from these effector cells was determined by an enzyme-linked immunosorbent assay. The cytotoxicity of hMSCs that overexpress the human AAT gene against HUVEC was evaluated with an apoptotic assay. Results: Lentivirus-transduced hMSCs produced functional AAT and displayed much higher cytotoxicity against HUVEC than untransduced hMSCs. Moreover, AAT secreted from transduced hMSCs significantly inhibited HUVEC proliferation compared to untransduced hMSCs. The data obtained demonstrate for the first time that genetically modified hMSCs released abundant and functional AAT that caused obvious cytotoxicity to HUVEC. Conclusions: hMSC may serve as an effective platform for the targeted delivery of therapeutic proteins to cancer sites.",
keywords = "α1-antitrypsin, Angiogenesis, Cancer gene therapy, Mesenchymal stem cells, Umbilical cord vein endothelial cells",
author = "Mahboobe Ghaedi and Masoud Soleimani and Taghvaie, {Narges Mohammad} and Mahmood Sheikhfatollahi and Keyhan Azadmanesh and Lotfi, {Abbas S.} and Jian Wu",
year = "2011",
month = "3",
doi = "10.1002/jgm.1552",
language = "English (US)",
volume = "13",
pages = "171--180",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors

AU - Ghaedi, Mahboobe

AU - Soleimani, Masoud

AU - Taghvaie, Narges Mohammad

AU - Sheikhfatollahi, Mahmood

AU - Azadmanesh, Keyhan

AU - Lotfi, Abbas S.

AU - Wu, Jian

PY - 2011/3

Y1 - 2011/3

N2 - Inhibition of tumor-induced angiogenesis may restrict tumor growth and metastasis. Long-term systemic delivery of angiogenic inhibitors is associated with toxicity, as well as other severe side-effects. The utility of cells as vehicles for gene therapy to deliver therapeutic molecules has been suggested to represent an efficient approach. Mesenchymal stem cells (MSCs) exhibit a tropism to cancer tissue, and may serve as a cellular delivery vehicle and a local producer of anti-angiogenic agents. Methods: In the present study, we attempted to assess production of the transgene, α1-antitrypsin (AAT), in lentivirus-transduced human MSCs and its cytotoxicity against human umbilical cord vein endothelial cells (HUVEC). The secreted protein from these effector cells was determined by an enzyme-linked immunosorbent assay. The cytotoxicity of hMSCs that overexpress the human AAT gene against HUVEC was evaluated with an apoptotic assay. Results: Lentivirus-transduced hMSCs produced functional AAT and displayed much higher cytotoxicity against HUVEC than untransduced hMSCs. Moreover, AAT secreted from transduced hMSCs significantly inhibited HUVEC proliferation compared to untransduced hMSCs. The data obtained demonstrate for the first time that genetically modified hMSCs released abundant and functional AAT that caused obvious cytotoxicity to HUVEC. Conclusions: hMSC may serve as an effective platform for the targeted delivery of therapeutic proteins to cancer sites.

AB - Inhibition of tumor-induced angiogenesis may restrict tumor growth and metastasis. Long-term systemic delivery of angiogenic inhibitors is associated with toxicity, as well as other severe side-effects. The utility of cells as vehicles for gene therapy to deliver therapeutic molecules has been suggested to represent an efficient approach. Mesenchymal stem cells (MSCs) exhibit a tropism to cancer tissue, and may serve as a cellular delivery vehicle and a local producer of anti-angiogenic agents. Methods: In the present study, we attempted to assess production of the transgene, α1-antitrypsin (AAT), in lentivirus-transduced human MSCs and its cytotoxicity against human umbilical cord vein endothelial cells (HUVEC). The secreted protein from these effector cells was determined by an enzyme-linked immunosorbent assay. The cytotoxicity of hMSCs that overexpress the human AAT gene against HUVEC was evaluated with an apoptotic assay. Results: Lentivirus-transduced hMSCs produced functional AAT and displayed much higher cytotoxicity against HUVEC than untransduced hMSCs. Moreover, AAT secreted from transduced hMSCs significantly inhibited HUVEC proliferation compared to untransduced hMSCs. The data obtained demonstrate for the first time that genetically modified hMSCs released abundant and functional AAT that caused obvious cytotoxicity to HUVEC. Conclusions: hMSC may serve as an effective platform for the targeted delivery of therapeutic proteins to cancer sites.

KW - α1-antitrypsin

KW - Angiogenesis

KW - Cancer gene therapy

KW - Mesenchymal stem cells

KW - Umbilical cord vein endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=79955162488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955162488&partnerID=8YFLogxK

U2 - 10.1002/jgm.1552

DO - 10.1002/jgm.1552

M3 - Article

C2 - 21449040

AN - SCOPUS:79955162488

VL - 13

SP - 171

EP - 180

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 3

ER -